LFMD
LFMD (LifeMD, Inc.) — telehealth and pharmacy services operator with subscription-based prescription and OTC product offerings. Recent SEC filings (10-Qs for 2025-09-30 and 2026-03-31) show sequential revenue growth, continued investment in capitalized software, recurring preferred dividends, a reduced convertible debt burden, a material weakness in internal controls disclosure, and classification of WorkSimpli as discontinued operations following a November 2025 sale of the majority interest.
Recent proof-backed thesis calls
Recent published active plays are SEC 10-Q filings: 2025-09-30 and 2026-03-31 quarterlies and the FY2025 10-K header. Filings include condensed and consolidated financial statements, disclosures of accumulated deficits (~$238–$248 million across periods), preferred stock dividends (Series A), capitalized software investment, and the sale/classification of WorkSimpli as discontinued operations.
The provided 10‑Q text is only the cover page/header (issuer identity, exchange listing, and registered securities) and does not include financial statements, MD&A, risk factors, guidance, liquidity discussion, or any operational updates. As a result, there is no substantive incremental information to form a bullish/bearish thesis or a trade with a defensible direction.
Cover page of LifeMD, Inc. (LFMD) FY2025 10-K (period ended 2025-12-31). No financial statements, guidance, risk-factor changes, or MD&A details provided in the excerpt, so actionable trading signals are limited. Identified listed securities: LFMD common and LFMDP preferred on Nasdaq Global Market.
The provided excerpt is only the cover/page header of LifeMD, Inc.’s Form 10‑Q for the quarter ended 2025‑09‑30. It identifies the registrant, exchange listing, and the two Nasdaq-traded securities (LFMD common and LFMDP preferred), but contains no financial statements, MD&A, guidance, risk updates, liquidity disclosures, or operational metrics. As-is, it is not sufficient to form an evidence-based bullish/bearish view from the filing content.
Excerpt is only the cover/header of LifeMD, Inc. (LFMD) Form 10-Q for quarter ended 2025-06-30. It confirms ticker/listings (LFMD common; LFMDP 8.875% Series A cumulative perpetual preferred) and that the company is current on SEC filing requirements. No financial statements, KPIs, guidance, risk-factor updates, or MD&A content provided, so investable conclusions are limited.
Latest market-close explanation
Market note: LFMD traded intraday strength in a recent session (+6.1% to $4.54) on light volume, likely a technical/sentiment bounce rather than a news-driven rally. Watch for follow-through above ~$4.60 on rising volume or failure back below ~$4.28–$4.25 to invalidate the move.
What most likely happened - LFMD slipped 4.1% to 4.70 on slightly lighter volume (volume down ~6%), with no company news or earnings to explain the move. - The pattern looks like routine profit-taking or a modest pullback prompted by broader market/sector weakness rather than a stock-specific event. The lack of a volume spike argues against a large institutional liquidation or major new information. What to watch next - Volume: a rise in selling volume would confirm heavier distribution; rising buying volume on a rebound would signal accumulation. - Key levels: short-term support near today’s low (~4.60–4.50); near-term resistance at the prior close/overnight supply around 4.90–5.00. A sustained move below 4.50 would be bearish; reclaiming and holding above 4.90 would be constructive. - News flow and filings: monitor for any press releases, SEC filings, analyst notes, or sector headlines that could explain or accelerate moves. - Market/sector context: check broader market direction and peers—if the whole sector is weak, the move is less company-specific. - Position management: if you’re long, consider trimming or using a tighter stop while waiting for volume-confirmed support; if trading, wait for a clear volume-backed reversal or breakdown before committing. Bottom line: likely a routine pullback on light volume — watch volume for confirmation and the 4.50–4.90 band for next directional clues.
Current stance
Sell. The research stance is a sell based on the quarter-ended 2026-03-31 10-Q and the 2025-09-30 10-Q filings (confidence ~60% each). Key drivers: meaningful net losses continuing, recurring preferred dividends, disclosures of a material weakness in internal controls, and ongoing cash use for capitalized software and operating needs. The 10-K cover/header provides only administrative confirmation and modest de-risking for capital-structure instruments but does not materially support equity upside.
- sell via LFMD 10-Q report for 2026-03-31 from https://www.sec.gov/edgar/search/ (confidence 0.60)
- sell via LFMD 10-Q report for 2025-09-30 from https://www.sec.gov/edgar/search/ (confidence 0.60)
- risk via Routine 10-K filing: modest de-risking for capital-structure instruments, limited standalone catalyst for common from https://www.sec.gov/edgar/search/ (confidence 0.25)
Top authors on this asset
Active and historical ticker theses
Active plays available on the ticker page are the company 10-Q filings (2025-09-30, 2026-03-31) and the FY2025 10-K header. The 2026-03-31 consolidated statements show: total assets ~$70.1M, total liabilities ~$55.1M, stockholders’ equity ~$15.0M (Mar 31, 2026), telehealth revenue for the quarter of $50.16M, a large operating loss from continuing operations ($8.87M for the quarter), and a continued Series A preferred dividend obligation. The 2025-09-30 10-Q shows nine‑month revenues of $187.0M, gross profit of $163.5M, operating loss narrowing versus prior year, and cash at Sept 30, 2025 of $23.79M.
LFMD 10-Q report for 2025-09-30
LFMD 10-Q report for 2026-03-31
Routine 10-K filing: modest de-risking for capital-structure instruments, limited standalone catalyst for common
Administrative filing removes delinquency/late-filing overhang (if market had any)
Unlock full asset monitoring
For investors: review the full 10-Qs (Sept 30, 2025 and Mar 31, 2026) for detailed financials, the material weakness disclosure, and the WorkSimpli disposition. If you hold common stock, consider trimming exposure; preferred holders should monitor dividend mechanics and liquidation preference. Source filings at https://www.sec.gov/edgar/search/.